BioSpace News Archive

Wilmington, Delaware, United States: For the lack of immunity power, which is only starting to grow since birth, neonatal or infant are more prone to several types of diseases than the adults.

Fact.MR – A Market Research and Competitive Intelligence Provider: The global gene therapy market advocates that the industry is poised to incline at an 18.5% value CAGR from 2022-2032, expected to close at a valuation of US$ 10.1 Billion.

Wilmington, Delaware, United States: Enzymes are biocatalysts and highly specialized for accelerating various types of chemical reactions without undergoing self-changes.

Wilmington, Delaware, United States: The growth of the global market viral inactivation hinges on to advancements in the fields of drug development, microbiology, and medication.

Avacta Group plc announces that the first-in-human Phase I trial of AVA6000 Pro-doxorubicin will advance to the third dose cohort following a positive review of the safety data from the dosing of the second cohort.

AlzeCure Pharma AB announced that the company has completed the clinical phase I study with repeated dosing of the drug candidate ACD856, with a focus on Alzheimer’s disease.

Aesthetic Medical International Holdings Group Limited, a leading provider of aesthetic medical services in China, announced its unaudited financial results for the first quarter ended March 31, 2022.

NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, today announced the promotion of William (Bill) Mann, Ph.D. to President of the Company, effective immediately.

The global leader in the fight against blood cancers, The Leukemia & Lymphoma Society (LLS), announced the launch of its Pediatric Acute Leukemia (PedAL) Master Clinical Trial, an unprecedented international collaboration led by LLS designed to fundamentally change how children with acute leukemias are treated.

Tryp Therapeutics , Inc. (CSE: TRYP) (OTCQB: TRYPF) (“Tryp” or the “Company”), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today the filing of a new provisional patent for the use of psilocybin for the treatment of patients with Binge Eating disorder (BED).